Arrowhead Pharmaceuticals Initiates Phase 2b Study of Investigational ARO-ANG3 for Treatment of Mixed Dyslipidemia

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals dosed the first patient in a Phase 2b clinical study of ARO-ANG3 an RNAi therapeutic to treat mixed dyslipidemia

Click to view original post